Aralez Pharma (ARLZ) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARLZ Hot Sheet
Join SI Premium – FREE
Aralez Pharma (NASDAQ: ARLZ) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $24.3 million versus the consensus estimate of $22.55 million.
GUIDANCE:
Aralez Pharma sees FY2017 revenue of $95-105 million, raised from prior range of $80-100 million.
Aralez Pharma sees FY2018 revenue of $140-160 million
For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Versant Corp. (VSNT) Reports Q3 EPS of $0.34 ; Offers Guidance
- Xometry, Inc. (XMTR) Tops Q3 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
